Expanding the Treatment of Migraine

CoLucid Pharmaceuticals was founded with a primary goal of developing lasmiditan for the acute treatment of migraine. The Company has three clinical trials underway—SAMURAI, SPARTAN, and GLADIATOR—which will result in more than 15,000 patient exposures with lasmiditan.

Lasmiditan is being developed in two formulations: an oral medication for the acute treatment of migraine in adults, and also as intravenous formulation for administration by health care professionals.

 

Corporate Governance

Find all CoLucid Committee Charters and Governance Documents.

Read More



Why We Do What We Do

Why We Do What We Do

At CoLucid, we are committed to helping people with serious neurological conditions and diseases such as migraine to improve their quality of life.  We are focused on the development and commercialization of innovative therapies to address patient populations that are significantly underserved and to improve their lives and daily function.

CoLucid Pharmaceuticals Video Overview

CoLucid Pharmaceuticals Video Overview

Learn More

View Our Annual Report

View Our Annual Report

Learn More

CoLucid Corporate Presentation

CoLucid Corporate Presentation

Get more in-depth information about our vision, our management team, our dedication to finding effective alternative therapies for migraine patients, and the status of clinical trials for lasmiditan.

Learn More